Treatment of hypertension in peripheral arterial disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Lane, Deirdre A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antihypertensive agents *therapeutic use ; Humans; Hypertension *drug therapy ; Intermittent claudication drug therapy ; Perindopril therapeutic use ; Peripheral vascular diseases *drug therapy ; Randomized controlled trials as topic; Verapamil therapeutic use

Indexed keywords

DOXAZOSIN; HYDROCHLOROTHIAZIDE; PERINDOPRIL; PLACEBO; RAMIPRIL; VERAPAMIL;

ANGIOPLASTY; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERTENSION; LEG ISCHEMIA; LIMB AMPUTATION; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STROKE; SYSTEMATIC REVIEW;

EID: 77950150466     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003075.pub2     Document Type: Review

References (100)

1. Hoogerbrugge 2002 {published data only} Hoogerbrugge N, de Groot E, de Heide LH, de Ridder MA, Birkenhageri JC, Stijnen T, Jansen H. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. Netherlands Journal of Medicine 2002;60(9):354-61.
2. HOPE 2004 {published and unpublished data} * Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S, HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal 2004;25(1):17-24.
3. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology 1996;12(2):127-37.
4. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. New England Journal of Medicine 2000;342(3):154-60.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. New England Journal of Medicine 2000;342(3):145-53.
6. Overlack 1994 {published data only} Overlack A, Adamczak M, Bachmann W, Bonner G, Bretzel RG, Derichs R, et al.ACE-inhibition with perindopril in essential hypertensive patients with comcomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group. American Journal of Medicine 1994;97(2):126-34.
7. Schweizer 1998 {published data only} Schweizer J, Kirch W, Koch R, Hellner G, Uhlmann K. Effect of high dose verapamil on restenosis after peripheral angioplasty. Journal of the American College of Cardiology 1998;31(6):1299-305.
8. ABCD 2003 {published data only} Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645-52.
9. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Controlled Clinical Trials 1996;17(3):242-57.
10. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107(5):753-6.
11. Ahimastos 2006 {published and unpublished data} Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. Journal of Hypertension 2008;26(5):1037-42.
12. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Annals of Internal Medicine 2006;144(9):660-4.
13. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45(6): 1194-9.
14. ASCOT 2005 {published and unpublished data} Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al.ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906.
15. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. Journal of Hypertension 2001;19(6):1139-47. [MEDLINE: 11403364]
16. Bernardi 1988 {published data only} Bernardi D, Bartoli P, Ferreri A, Geri AB, Ieri A. Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology 1988;39(11):942-52.
17. Bogaert 1983 {published data only} Bogaert MG, Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. European Heart Journal 1983;4(3):203-4.
18. Bostrom 1986 {published data only} Bostrom PA, Janzon L, Ohlsson O, Westergren A. The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication. Angiology 1986;37(3 Pt 1):149-53.
19. Branchereau 1995 {published data only} Branchereau A, Rouffy J. Randomised double-blind two parallel-groups ifenprodil tartrate versus placebo-controlled trial in stage II peripheral arterial occlusive disease. Journal des Maladies Vasculaires 1995;20(1):21-7.
20. Brown 1998 {published data only} Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Journal of Hypertension 1998;16(12 Pt 2):2113-6.
21. Casiglia 1997 {published data only} Casiglia E, Petucco S, Pessina AC. Antihypertensive efficacy of amlodipine and enalapril and effects on peripheral blood flow in patients with essential hypertension and intermittent claudication. Clinical Drug Investigation 1997;13 Suppl 1:97-101.
22. Coto 1989 {published data only} Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Coto F, et al.Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989;40:880-5.
23. Coto 1991 {published data only} Coto V, Oliviero U, Cocozza M, Lucariello A, Picano T, Coto F. A comparative trial of ketanserin and nifedipine in hypertension and obstructive peripheral arteriopathy. Advances in Therapy 1991;8(3):133-40.
24. Diehm 1993 {published data only} Diehm C, Jacobsen O, Amendt K. The effects of tertatolol on lipid profile. Cardiology 1993;83 Suppl 1:32-40.
25. Hiatt 1985 {published data only} Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985;72(6):1226-31.
26. Ingram 1982 {published data only} Ingram DM, House AK, Thompson GH, Stacey MC, Castleden WM, Lovegrove FT. Beta-adrenergic blockade and peripheral vascular disease. Medical Journal of Australia 1982;1(12):509-11.
27. INVEST 2003 {published data only} Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, et al.Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. American Heart Journal 2008;156(2):241-7.
28. Pepine CJ, Handberg EM, Cooper-Dehoff RM, Marks RG, Kowey P, Messerli FH, et al.A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290(21):2805-16.
29. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology 1998;32(5):1228-37.
30. Zineh I, Cooper-Dehoff RM, Wessel TR, Arant CB, Sleight P, Geiser EA, et al.Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST). Clinical Cardiology 2005;28(7):321-8.
31. Kalus 1995 {published data only} Kalus U, Jung F, Scheurer K, Koscielny J, Radtke H, Kiesewetter H, et al.The alpha and beta blocker carvediol in the treatment of hypertensive patients with POAD. Clinical Hemorheology 1995;15:570.
32. Klieber 1986 {published data only} Klieber M, Resch F. Comparative studies of the effect of a cardioselective and a noncardioselective beta-blocker on peripheral circulation in patients with arterial occlusive disease [Vergleichende Untersuchengen uber die Werkung eines Kardioselektiven und eines Nichtkardioselektiven Betablockers auf die Periphere Durchblutung von Patienten mit Arterieller Verschlusskrankheit]. Weiner Klinische Wochenschrift 1986;98(3):70-3.
33. Larsen 1969 {published data only} Larsen OA, Lassen NA. Medical treatment of occlusive arterial disease of the legs. Walking exercise and medically induced hypertension. Angiologica 1969;6(5):288-301.
34. Laurent 1994 {published data only} Laurent S, Becquemont L, Laloux B, Asmar R, Hugue C, Vayssairat M, et al.Haemodynamic effects of chronic treatment by cilazapril in normotensive patients with obliterative arterial disease of the lower limbs [Effets hemodynamiques d'un traitement chronique par le cilazapril chez les malades normotendus atteints d'arteriopathie obliiterante des membres inferieurs]. Archives des Maladies du Coeur et des Vaisseaux 1994;87(8):987-90.
35. Leeman 1995 {published data only} Leeman M, Degaute J-P. Invasive haemodynamic evaluation of sublingual captopril and nifedipine in patients with arterial hypertension after abdominal aortic surgery. Critical Care Medicine 1995;23(5):843-7.
36. Lepantalo 1983 {published data only} Lepantalo M, Totterman KJ. Effect of long term beta-adrenergicblockade on calf blood flow in hypertensive patients. Clinical Physiology 1983;3(1):35-42.
37. Lepantalo 1984 {published data only} Lepantalo M, von Knorring J. Walking capacity of patients with intermittent claudication during chronic antihypertensive treatment with metoprolol and methyldopa. Clinical Physiology 1984;4(4):275-82.
38. Lepantalo 1985a {published data only} Lepantalo M. Beta blockade and intermittent claudication. Acta Medica Scandinavica. Supplementum 1985;700:1-48.
39. * Lepantalo M. Chronic effects of labetolol, pindolol and propranolol on calf blood flow in intermittent claudication. Clinical Pharmacology and Therapeutics 1985;37(1):7-12.
40. Lepantalo M, Lindstrom BL, Totterman KJ. Adrenoreceptor blocking drugs and cold feet in intermittent claudication. Vasa 1986;15(2):135-7.
41. Lepantalo 1985b {published data only} Lepantalo M, Aromaa A, Klaukka T, Lukkari E. Does betablockade provoke intermittent claudication?. Acta Medica Scandinavica 1985;218(1):35-9.
42. Liakishev 2008 {published data only} Liakishev AA. Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial [Russian]. Kardiologiia 2008;48(5):72.
43. Lievre 1996 {published data only} Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. Journal of Cardiovascular Pharmacology 1996;27(6):788-93.
44. LIFE 2002 {published and unpublished data} Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al.The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. American Journal of Hypertension 1997;10(7 (Part 1)):705-13.
45. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al.LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
46. Liu 1997 {published data only} Liu Y, Opitz-Gress A, Rott A, Liewald F, Sunder-Plassmann L, Lehmann M, et al.Effect of felodipine on regional blood supply and collateral vascular resistance in patients with peripheral arterial occlusive disease. Vascular Medicine 1997;2(1):13-8.
47. Mann 1998 {published data only} Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7(3):176-83.
48. Natali 1989 {published data only} Natali J, Kieny R, Le Bas P, Benhamou M, Molkhou JM. Ifenprodil tartrate in the treatment of occlusive arteriopathies of the lower limbs. Results of a prospective double-blind controlled mulitcentre trial [Le tartrate d'ifenprodil dans le traitement des arteriopathies obliterantes des membres inferieures]. Annales de Cardiologie et d'Angeiologie 1989;38(6):339-42.
49. Novo 1985 {published data only} Novo S, Pinto A, Galati D, Giannola A, Forte G, Strano A. Effects of chronic administration of selective betablockers on peripheral circulation of the lower limbs in patients with essential hypertension. International Angiology 1985;4(2):229-34.
50. Novo 1986 {published data only} Novo S, Alaimo G, Abrignani MG, Giordano U, Avellone G, Pinto A, et al.Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. International Journal of Clinical Pharmacology Research 1986;6(3):199-211.
51. Novo 1996 {published data only} Novo S, Abrignani MG, Pavone G, Zamueli M, Pernice C, Geraci AM, et al.Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. International Angiology 1996;15(2):169-74.
52. ONTARGET 2008 {published and unpublished data} ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358(15):1547-59.
53. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al.ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal 2004;148(1):52-61.
54. OPERA 2002 {published data only} Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber M, et al.Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. American Journal of Hypertension 2002;15(2 Pt 1):193-8.
55. Panzner 1992 {published data only} Panzner B, Haringer E. Efficacy and tolerability of celiprolol and enalapril in patients with essential hypertension. Journal of Drug Development 1992;5(2):83- 7.
56. POISE 2008 {published data only} POISE study group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627):1839-47.
57. Reichert 1975 {published data only} Reichert N, Shibolet S, Adar R, Gafni J. Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics 1975;17(5): 612-5.
58. Roberts 1987 {published data only} Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2(8560):650-3.
59. Roberts 1992 {published data only} Roberts DH, Tsao Y, Linge K, Chatlani PT, McLoughlin GA, Breckenridge AM. Double-blind comparison of captopril or nifedepine in hypertension complicated by intermittent claudication. British Journal of Clinical Pharmacology 1988;25(5):631P-2P.
60. * Roberts DH, Tsao Y, Linge K, McLoughlin GA, Breckenridge A. Double-blind comparison of captopril with nifedepine in hypertension complicated by intermittent claudication. Angiology 1992;43(9):748-56.
61. Rouffy 1989 {published data only} Rouffy J, Djian F, Barret A, Branchereau A, Chevalier JM, Cristol R, et al.Ifenprodil tartrate for the treatment of chronic obliterating arteriosclerosis of the lower limbs with intermittent claudication. A multicentre, prospective, randomised, double-blind trial versus placebo [Le tartrate d'ifenprodil dans le traitement de l'arteriopathie chronique obliterante des membres inferieurs. Au stade de la claudication intermittente.]. Semaines des Hopitaux 1989;65(33): 2071-6.
62. Schweizer 1996 {published data only} Schweizer J, Kaulen R, Altman E, Nierade A, Nanning T. Are betablockers always contraindicated in peripheral arterial occlusive disease? [Sind Betablocker bei Patienten mit Peripherer Arterieller Verschlusskrankheit Generell Kontraindiziert?]. Zeitschrift fur Kardiologie 1996;85(3):193-7.
63. Schweizer J, Kaulen R, Nierade A, Altman E. Beta blockers and nitrates in patients with peripheral arterial occlusive disease: long term findings. Vasa 1997;26(1):43-6.
64. Siniscalchi 1993 {published data only} Siniscalchi N, De Nicola A, Misso L, Cerciello T, Carbone L, Molisso A. Treatment and monitoring of obstructive peripheral arterial disease in elderly with systolic hypertension. International Angiology 1993;12:76.
65. Smith 1982 {published data only} Smith RS, Warren DJ. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. Journal of Cardiovascular Pharmacology 1982;4(1):2- 4.
66. Solomon 1991 {published data only} Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedepine and their combination. BMJ 1991;303(6810):1100-4.
67. Spence 1993 {published data only} Spence JD, Arnold JMO, Munoz CE, Vishwanatha A, Huff M, Derose G, et al.Angiotensin-converting enzyme inhibition with cilazapril does not improve blood flow, walking time, or plasma lipids in patients with intermittent claudication. Journal of Vascular Medicine and Biology 1993;4(1):23-8.
68. Stumpe 1993 {published data only} Stumpe KO, Overlack A. A new trial of the efficacy, tolerability and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). American Journal of Cardiology 1993;71(17):32E-7E.
69. Stumpe 1995 {published data only} Stumpe KO, Ludwig M, Heagerty AM, Kolloch RE, Mancia G, Safar M, et al.Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. American Journal of Cardiology 1995;76(15):50E-4E.
70. Sutton-Tyrell 1995 {published data only} Sutton-Tyrell K, Alcorn HG, Herzog H, Kelsey SF, Kuller LH. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995;26(8):1319-24.
71. Svendsen 1986 {published data only} Svendsen TL, Jelnes R, Tonnesen KH. Is adrenergic betareceptor blockade contraindicated in patients with intermittent claudication?. Acta Medica Scandinavica. Supplementum 1985;693:129-32.
72. * Svendsen TL, Jelnes R, Tonnesen KH. The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication. Acta Medica Scandinavica 1986;219(2):161-5.
73. VALUE 2006 {published data only} Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.
74. Mann J, Julius S for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7:176-83.
75. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al.Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. Journal of Hypertension 2006;24(11):2163-8.
76. Van de Ven 1994 {published data only} Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 1994;23(4):357-62.
77. Weibull 1992 {published data only} Weibull H, Bergentz S, Bergqvist D, Hulthen L, Manhem P, Jonsson K, et al.Percutaneous transluminal angioplasty vs reconstructive renovascular surgery in atherosclerotic unilateral renal artery stenosis - a prospective randomised study. Journal of Vascular Surgery 1992;15(6):1058.
78. Bauwens 1989 Bauwens F, Duprez D, Van Wassenhove A, Brusselmans F, Clement DL. Localisation and risk factors of peripheral arterial occlusive disease in the female. International Angiology 1989;8(1):32-5.
79. Binaghi 1994 Binaghi F, Fronteddu PF, Cannas F, Caredda E, Uras A, Garau P, et al.Prevalence of peripheral arterial occlusive disease and associated risk factors in a sample of southern Sardinian population. International Angiology 1994;13(3):233-45.
80. Bowlin 1997 Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Yaari S, Goldbourt U. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Annals of Epidemiology 1997;7(3):180-7.
81. Breckenridge 1992 Breckenridge A, Roberts D, Walley T. Different vasodilating mechanisms - different peripheral effects?. Journal of Cardiovascular Pharmacology 1992;19 Suppl 1:S23-6.
82. Cheng 1999 Cheng SW, Ting AC, Lau H, Wong J. Epidemiology of atherosclerotic peripheral arterial occlusive disease in Hong Kong. World Journal of Surgery 1999;23(2):202-6.
83. Cochrane 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008.
84. Fontaine 1954 Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;5/6:491-533.
85. Fowkes 1992 Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, et al.Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. American Journal of Epidemiology 1992;135(4):331-40.
86. Hjalmarson 1997 Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. American Journal of Cardiology 1997;80(9B):35J-39J.
87. Hope 1996 The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology 1996;12(2):127-37.
88. Johnston 1988 Johnston KW, Rae M, Steiner G, Kalman PG, Schwartz L, Hill ME, et al.An atherosclerosis risk factor assessment program for patients with peripheral arterial occlusive disease. Annals of Vascular Surgery 1988;2(2):101-7.
89. Kannel 1974 Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Progress in Cardiovascular Diseases 1974;17(1):5-24.
90. Kannel 1996 Kannel WB. The demographics of claudication and the aging of the American population. Vascular Medicine 1996;1(1):60- 4.
91. Makin 2001 Makin A, Lip GYH, Silverman S, Beevers DG. Peripheral vascular disease and hypertension: a forgotten association?. Journal of Human Hypertension 2001;15(7):447-54.
92. Makin 2002 Makin A, Silverman SH, Lip GY. Peripheral vascular disease and Virchow's triad for thrombogenesis. QJM 2002;95(4): 199-210.
93. McGill 1998 McGill HC Jr, McMahan CA, Tracy RE, Oalmann MC, Cornhill JF, Herderick EE, et al.Relation of a postmortem renal index of hypertension to atherosclerosis and coronary artery size in young men and women. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arteriosclerosis Thrombosis & Vascular Biology 1998;18(7): 1108-18.
94. Novo 1992 Novo S, Avellone G, Di Garbo V, Abrignani MG, Liquori M, Panno AV, et al.Prevalence of risk factors in patients with peripheral arterial disease. A clinical and epidemiological evaluation. International Angiology 1992;11(3):218-29.
95. Ostergren 2004 Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S, HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal 2004;25(1):17-24.
96. Ramsay 1999 Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al.Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Journal of Human Hypertension 1999;13(9):569-92.
97. Reunanen 1982 Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Medica Scandinavica 1982;211(4):249-56.
98. Simon 1986 Simon AC, Levenson J, Maarek B, Bouthier J, Safar ME. Evidence of early changes of the brachial artery circulation in borderline hypertension. Journal of Cardiovascular Pharmacology 1986;8(Suppl 5):S36-8.
99. Violi 1996 Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis 1996;120(1-2):25-35.
100. Cochrane 2003 Lip GYH, Makin AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD003075]